Temasek Leads Series B in Ascus Biosciences
Posted on 05/28/2020
San Diego-based Ascus Biosciences, Inc. raised US$ 46 million in a Series B round led by Singapore’s Temasek Holdings. Other investors in the round include Anterra Capital, Formation 8, and Cavallo Ventures (the venture capital arm of Wilbur-Ellis), and additional support from various angel investors. Ascus plans to use the capital proceeds to enhance its customer sales and servicing teams, advance new and existing products in its product pipeline, and continue refining its core technology platform and intellectual property foundation.
According to the press release, “Ascus uses its proprietary technology platform to resolve the complexities in the native microbial communities living in highly productive and healthy animals. From these curated insights, efficacious native microorganisms are selected and isolated from animal samples and developed into products. These novel, multi-strain and naturally occurring whole microbe products are shelf stabilized and compatible with standard in-feed delivery systems.”
